
    
      Patients will have tests and exams to see if they are eligible for the clinical trial. If
      found eligible, the patient will receive treatment with Niraparib daily and dostarlimab by
      vein every three weeks for 4 cycles then every six weeks.

      Patients will receive the study treatment as long as there is evidence that the tumor is not
      growing or spreading and they are not having any unacceptable, bad side effects.

      Patients will be monitored during treatment with tests and exams and after treatment
      completion for up to 5 years.
    
  